Product Description
ALTA-2618, an orally bioavailable, mutant-selective, and covalent allosteric inhibitor of AKT1 E17K. (Sourced from: https://www.alterome.com/programs/)
Mechanisms of Action: AKT1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alterome Therapeutics, Inc.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|